Once-weekly semaglutide (marketed as Ozempic), Novo Nordisk's latest innovation in diabetes medication, helps manage blood sugar and body weight, and reduces the risk of heart problems, for people living with type 2 diabetes1-5 Novo Nordisk, a global pharmaceutical company specialized in diabetes, announced that once-weekly Ozempic for the treatment of type 2 diabetes, is now available in Egypt. Alongside diet and exercise, Ozempic can either be used alone or in addition to other products for diabetes management. Hesham El Hefnawy, professor of diabetes and endocrinology, said: "Type 2 diabetes is a complex disease. It develops when a person's body cannot effectively use, or cannot make enough insulin, which helps regulate how much sugar is in the blood. Without insulin, too much sugar stays in the bloodstream where it can cause damage to vital organs and result in serious health problems.7 " "I see many people in my clinic each week with uncontrolled diabetes; in fact, nearly half the people living with type 2 diabetes do not have their condition in control, and are at risk of serious complications, such as cardiovascular disease, kidney diseases, retinopathy and neuropathy," said Yehia Ghanem, professor of diabetes and metabolism, Alexandria University. "With its superior and unique clinical profile, we believe that Ozempic has the potential to set a completely new standard for treatment of type 2 diabetes. Due to its outstanding clinical benefits As well as reduction of cardiovascular diseases risk by 26%" When the condition is well managed, the risk of life-limiting and potentially fatal complications can be reduced. Said professor Samir George Professor of internal medicine and diabetes, Cairo University "Ozempic is available in Egypt following a series of clinical trials involving over 10,000 adults with type 2 diabetes. The results consistently showed greater reductions in both blood sugar and body weight compared with commonly used treatments for type 2 diabetes, as well as cardiovascular benefits, in people with type 2 diabetes." elaborated professor Abbas Oraby, Professor of Diabetes and Endocrinology, Zagazig University "We are committed to developing new medicines for people living with diabetes and are delighted that Ozempic is now available in Egypt," said Ayman Hassan, Vice President and General Manager for Novo Nordisk. "As a once-weekly treatment which shows a remarkable ability to lower blood sugar, as well as reductions in body weight of up to 6.5 kg and a significant reduction in the risk of cardiovascular events such as stroke and heart attack, we believe Ozempic will help meet the real and serious needs of those living with this condition."
